Kinetics of maternally-derived serogroup A, C, Y and W-specific meningococcal immunoglobulin G in Malian women and infants

Helen Findlow*, M. D. Tapia, S. O. Sow, F. C. Haidara, F. Coulibaly, A. M. Keita, F. Diallo, M. Doumbia, A. Traore, N. Schluterman, D. A. Clark, Raymond Borrow, M. M. Levine

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)


A prospective, randomised, controlled observer-blind trial measuring the efficacy and immunogenicity of trivalent influenza vaccine (TIV) and the immunogenicity of quadrivalent meningococcal conjugate vaccine (MCV) in pregnant women and their infants up to 6 months of age was conducted in Mali. Here we reported the immunogenicity of MCV, which was used as a comparator vaccine to TIV, in this population. Third-trimester pregnant Malian women were randomized to receive TIV or MCV. Blood samples were collected from women prior to vaccination, 28 days post-vaccination, at delivery and 3 and 6 months post-delivery and from infants at birth and 3 and 6 months of age. Meningococcal-specific serogroup (Men) A, C, Y and W-specific antibodies were measured by enzyme linked immunosorbent assay in a randomly selected subset of 50 mother-infant pairs where the mother had received MCV. At birth, 94.0% (47/50) of infants had MenA specific IgG levels ≥ 2 µg/mL decreasing to 72.9% and 30.4% at 3 and 6 months of age. For MenC, 81.3% (39/48) of infants had MenC specific IgG levels ≥ 2 µg/mL at birth decreasing to 29.4% and 17.8% at 3 and 6 months of age. For MenY, 89.6% (43/48) of infants had MenY specific IgG levels ≥ 2 µg/mL at birth decreasing to 64.6% and 62.5% at 3 and 6 months of age. For MenW, 89.6% (43/48) of infants had MenW specific IgG levels ≥ 2 μg/ml at birth decreasing to 62.5% and 41.7% at 3 and 6 months of age. Maternal immunization with MCV conveyed protective levels of IgG at birth through to 3 months of age in the majority of infants.

Original languageEnglish
Pages (from-to)2477-2481
Number of pages5
Issue number18
Publication statusPublished - 24 Apr 2019

Bibliographical note

Funding Information:
Funding for the overall trial was from the Bill and Melinda Gates Foundation and this part of the work was funded by Sanofi Pasteur. HF and RB have performed contract research on behalf of Public Health England for Alexion, GSK, Merck, PATH, Pfizer Inc, Sanofi Pasteur, Serum Institute of India, and Takeda. MT, FH, FC, AMK, FD, MD, AT, NS, and MML have no disclosures to declare. SS is currently the Minister of Health of Mali.

Funding Information:
The principle of maternal immunization is supported by data for vaccination against tetanus, influenza and pertussis [1–4] . Immunization with the acellular pertussis vaccine has proven to increase the level of maternal antibodies and protect infants from clinical pertussis. Maternal pertussis vaccination was introduced in the U.K. in 2012, in response to an increase in infant deaths. This maternal vaccination program impacted on infant pertussis, with vaccine effectiveness being >90% for those infants who’s mother received a pertussis vaccine at least 1 week prior to delivery [3,4] . In principle maternal immunization can be applied to other vaccines and infectious diseases. However, it has been reported that maternal immunization with a pneumococcal polysaccharide vaccine does not protect infants against clinical disease [5] .

Publisher Copyright:
© 2019


  • Maternal immunization
  • Meningococcal
  • Vaccination


Dive into the research topics of 'Kinetics of maternally-derived serogroup A, C, Y and W-specific meningococcal immunoglobulin G in Malian women and infants'. Together they form a unique fingerprint.

Cite this